The US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee plans to meet on 22 October to discuss matters related to authorization and licensure of vaccines for COVID-19. No application will be on the docket at that meeting.
 
The announcement via the Federal Register and the FDA’s Twitter account comes a day after the head of the key US vaccine research accelerator Operation Warp Speed (OWS) signaled that a COVID-19 vaccine might be authorized or approved by the end of 2020. Both OWS and FDA communications emphasized a continuing commitment to relying on data in vaccine decisions, despite political pressure and medical need for vaccine approval.

Read more